.com is pleased to announce a new interview with Sean Carrick, of Nascent , Inc. (OTCPink:)

Nascent Biotech - theStockRadio


Name: , Inc.
Trading Symbol: NBIO
Quote: http://www.otcmarkets.com/stock/NBIO/quote
Co. Website: http://www.nascentbiotech.com/
Address: 8400 Miriamar Drive, Suite 247, San Diego, CA 92126
Phone: (612) 961-5656
Email: lowell.holden@nascentbiotech.com
: $26,193,670
Auth Shares: 100,000,000
Outstanding: 18,064,600
Public Float: 929,400
(All information was obtained from OTCmarkets.com)

NBIO BioTech - theStockRadioNascent Biotech is a -based company focused on the development and delivery of antibodies and cytokine responses for the treatment of .

The innate ability of the intelligence of the natural human immune system to generate a cancer specific response combined with Nascent Biotech’s technical skills opens the door for immunologically based therapeutics for human cancer.

Nascent Biotech is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.

“We are very encouraged by the early feedback in the current toxicology trials. Using the CHO-derived pritumumab, we are attempting to show the same minimal toxicity profile displayed in previous trials, but at significantly higher doses. About half way through the current trial we are seeing similar results. This should serve Nascent well going into the Phase I-II human trials later this year.” – Dr. Mark Glassy

Our insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.

The company’s technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce effective immune boosting and regulation biomolecules.

In our bodies, the natural immune response to harmful agents is both oligoclonal and oligocelluar; that is, several different antibodies and cell types are generated to attach a particular disease agent.

Use of a single monoclonal antibody (mAB), or monotherapy, to treat a disease – the approach employed by most pharmaceutical / biotechnology companies – may not be optimal and is certainly not the preferred natural approach.

Nascent Biotech’s approach to treatment of disease is to “mimic” the body’s natural antibody and cellular reponses by identifying and combining antibodies and natural cytokines into a single therapy for more effective disease treatment.

Nascent Biotech believes that by combining specifically selected biomolecules into a potent “cocktail”, one can create an efficient, multi-targetted attack against disease. Applications of this technology span cancer, metabolic disorders and infectious disease indications.

products NBIO - theStockRadio

Nascent Biotech’s lead product, Pritumumab, a natural human antibody, has been used to treat 250 brain cancer patients.

After 5 years, patients treated with Pritumumab have an overall survival rate of 25-30%, compared to 3% standard therapy, demonstrating antibodies are safe and effective.

The United States Patent Office has issued 11 patents for Pritumumab: 4618577; 4761377; 5093261; 5155036; 5286647; 5589573; 5602027; 6051229; 6051387; 6051693; 6165467.

Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer.

The recognized target is ecto-domain vimentin that is expressed on the cell surface of a variety of adenocarcinomas, including brain cancers and melanoma, but not expressed by normal tissues and cells.

In various Phase II clinical trials in Japan patients with brain cancer treated with Pritumumab showed an overall response rate between 25–30% with several survivors beyond 5-years post-treatment. Toxicities were minimal suggesting Pritumumab is a safe and effective therapeutic agent for the treatment of patients with brain cancer.


Nascent Biotech has been awarded 4 patents on CLNH5 from the United States Patent Office: 4618577; 6051229; 6051387; 6090924.


MultiPharm™ is a platform technology proprietary to Nascent Biotech that may have additive and synergistic effects not only for cancer therapy but also diabetes, autoimmunity, and transplantation.

MultiPharm™ uses multiple agents (antibodies and/or cytokines).



1 Comment